What Diseases Can Recombinant Human Interferon Treat?
Recombinant human interferon is a type of medical product that plays a significant role in the treatment of malignant tumors, severe hepatitis, and early cirrhosis. It also exhibits therapeutic effects in treating injuries and infectious diseases, as well as related conditions such as myelodysplastic syndromes. When using recombinant human interferon, it is essential to follow medical advice to avoid adverse reactions.
Here's a closer look at what recombinant human interferon treats:
1. Therapeutic Uses of Recombinant Human Interferon
Interferon itself is a glycoprotein with high species specificity. Its primary functions include antiviral activity, inhibition of cell proliferation, immune regulation, and antitumor effects. Clinically, interferon is primarily used to treat advanced capillary leukemia, renal cancer, melanoma, chronic myelogenous leukemia, and can also be used for breast cancer, head and neck cancer, and bladder cancer. It is mainly targeted at patients who are unable to undergo surgery or who perceive surgical risks as too high and are unwilling to undergo surgical treatment.
2. Adverse Reactions
The most common adverse reaction is fever, mostly low-grade (below 38°C), which resolves spontaneously after a few hours. A few patients may experience fatigue, discomfort, headache, muscle pain, joint pain, loss of appetite, nausea, and other adverse reactions. Common laboratory abnormalities include transient granulocytopenia and thrombocytopenia. If severe adverse reactions occur, the dose should be reduced or discontinued, and symptomatic treatment should be administered.
3. Dosage and Administration
For vaginal administration, place the suppository in the posterior fornix of the vagina, one suppository at a time, every other day, before bedtime. A course of treatment consists of 6-10 administrations or as prescribed by a doctor. Use under the guidance of a clinician with clinical experience. Dissolve each suppository with 1ml of sterile water for injection and administer by intramuscular or subcutaneous injection. Recommended dosages and durations are as follows:
Hairy cell leukemia: 40-60μg, injected once daily for over six months. The dosage may be adjusted based on the condition, and administration may be reduced to once every other day after remission.
Chronic hepatitis B and C: 40μg (20-60μg), injected once daily or reduced to three times weekly after four weeks of treatment, for a continuous period of 3 months or longer.
